Extracorporeal blood treatment (EBT) methods in SIRS/sepsis

被引:53
作者
Bellomo, R
Honoré, P
Matson, J
Ronco, C
Winchester, J
机构
[1] Austin Hosp, Dept Intens Care, Melbourne, Vic 3084, Australia
[2] Austin Hosp, Dept Med, Melbourne, Vic 3084, Australia
[3] Univ Melbourne, Melbourne, Vic, Australia
关键词
extracorporeal blood treatment (EBT) methods; SIRS/Sepsis; consensus; ADQI III conference;
D O I
10.1177/039139880502800505
中图分类号
R318 [生物医学工程];
学科分类号
0831 ;
摘要
Background: Extracorporeal blood purification treatment (EBT) methods have been used in the treatment of experimental and human SIRS/Sepsis in a variety of settings and with variable reports of efficacy and safety. Their role in the management of SIRS/Sepsis remains controversial. Objectives: To develop consensus statements regarding important aspects of research, practice and technical management concerning EBT Methods: Systematic review of published study. Evidence-based grading of information available. Consensus development regarding fundamental questions about EBT Results: Consensus was achieved on all questions posed during the conference. It was agreed that there is currently a clear biological rational for EBT in SIRS and Sepsis. It was agreed that conventional CVVH has sufficiently been shown not to be effective in SIRS/Sepsis in the absence of concomitant ARF and that other therapies such as plasmapheresis or high-volume hemofiltration or coupled plasma filtration adsorption appear more promising and should be tested in multicentre randomized controlled trials. Patients with ARF and SIRS/Sepsis should be treated differently from those with ARF alone even though current practice in this field is not well known. Patients with refractory septic shock should be considered for EBT Appropriate end points for clinical trials can be defined and chosen according to the goals of the trial. Different technologies exist for EBT and better understanding of the merits and safety of each is needed as well as better standardization of methodology and dose. Conclusions: Broad consensus can be achieved on several aspects of EBT and can be used to inform clinical practice and to help guide the establishment of a future research agenda.
引用
收藏
页码:450 / 458
页数:9
相关论文
共 53 条
[1]  
BEAT M, 2000, CRIT CARE MED, V28, P977
[2]   The Acute Dialysis Quality Initiative - Part II: Patient selection for CRRT [J].
Bellomo, R ;
Angus, D ;
Star, RA .
ADVANCES IN RENAL REPLACEMENT THERAPY, 2002, 9 (04) :255-259
[3]   TREATMENT OF SEPSIS-ASSOCIATED SEVERE ACUTE-RENAL-FAILURE WITH CONTINUOUS HEMODIAFILTRATION - CLINICAL-EXPERIENCE AND COMPARISON WITH CONVENTIONAL DIALYSIS [J].
BELLOMO, R ;
FARMER, M ;
WRIGHT, C ;
PARKIN, G ;
BOYCE, N .
BLOOD PURIFICATION, 1995, 13 (05) :246-254
[4]   DEFINITIONS FOR SEPSIS AND ORGAN FAILURE AND GUIDELINES FOR THE USE OF INNOVATIVE THERAPIES IN SEPSIS [J].
BONE, RC ;
BALK, RA ;
CERRA, FB ;
DELLINGER, RP ;
FEIN, AM ;
KNAUS, WA ;
SCHEIN, RMH ;
SIBBALD, WJ .
CHEST, 1992, 101 (06) :1644-1655
[5]   Effects of early high-volume continuous venovenous hemofiltration on survival and recovery of renal function in intensive care patients with acute renal failure: A prospective, randomized trial [J].
Bouman, CSC ;
Oudemans-van Straaten, HM ;
Tijssen, JGP ;
Zandstra, DF ;
Kesecioglu, J .
CRITICAL CARE MEDICINE, 2002, 30 (10) :2205-2211
[6]   Practical aspects of randomization and blinding in randomized clinical trials [J].
Bridgman, S ;
Dainty, K ;
Kirkley, A ;
Maffulli, N .
ARTHROSCOPY-THE JOURNAL OF ARTHROSCOPIC AND RELATED SURGERY, 2003, 19 (09) :1000-1006
[7]   Plasmapheresis in severe sepsis and septic shock: a prospective, randomised, controlled trial [J].
Busund, R ;
Koukline, V ;
Utrobin, U ;
Nedashkovsky, E .
INTENSIVE CARE MEDICINE, 2002, 28 (10) :1434-1439
[8]   PLASMA CYTOKINE AND ENDOTOXIN LEVELS CORRELATE WITH SURVIVAL IN PATIENTS WITH THE SEPSIS SYNDROME [J].
CASEY, LC ;
BALK, RA ;
BONE, RC .
ANNALS OF INTERNAL MEDICINE, 1993, 119 (08) :771-778
[9]   Dose determinants in continuous renal replacement therapy [J].
Clark, WR ;
Turk, JE ;
Kraus, MA ;
Gao, DY .
ARTIFICIAL ORGANS, 2003, 27 (09) :815-820
[10]   A phase II randomized, controlled trial of continuous hemofiltration in sepsis [J].
Cole, L ;
Bellomo, R ;
Hart, G ;
Journois, D ;
Davenport, P ;
Tipping, P ;
Ronco, C .
CRITICAL CARE MEDICINE, 2002, 30 (01) :100-106